Document:

Prepared and filed by St Ives Burrups

Exhibit
      10.27

EASTVIEW HOLDINGS LLC

777 Old Saw Mill River Road

Tarrytown, New York 10591

                                                                            October 23, 2003

BY HAND

Progenics Pharmaceuticals, Inc.

777 Old Saw Mill River Road

Tarrytown, New York 10591

Attention: Mr. Robert McKinney

	 	 	Re:	
 Lease dated as of September 30, 2003 between Eastview Holdings LLC (“Landlord”), and Progenics Pharmaceuticals, Inc. (“Tenant”) for space in the project known as The Landmark at Eastview (the “Lease”)                              

Gentlemen:

     This letter agreement is intended to amend Section 37.1 of the Lease.  The date of “October 23, 2003” as set forth in Section 37.1 of the Lease is hereby deemed deleted and replaced with the date “November 24, 2003”.

	 	 	 	 	 	Very truly yours,

	 	 	 	 	 	 
	 	 	 	 	 	EASTVIEW HOLDINGS LLC

	 	 	 	 	 	 
	 	 	 	 	 	By: EASTVIEW SPE INC, its Managing Member
	 	 	 	 	 	 
	 	 	 	 	 	By:/s/ Peter Gilpatric
	 	 	 	 	 	Name: Peter Gilpatric
	 	 	 	 	 	Title: Senior Vice President

                                                 

ACKNOWLEDGED AND AGREED:

PROGENICS PHARMACEUTICALS, INC.

By: /s/ Robert A. McKinney

   Robert A. McKinney

   Vice President<PAGE>

                                                                    Exhibit 10.3

                         EXECUTIVE EMPLOYMENT AGREEMENT

         This EXECUTIVE EMPLOYMENT AGREEMENT (the "Agreement") dated September
23, 2003 by and between Callisto Pharmaceuticals, Inc., a company incorporated
under the laws of Florida (the "Company"), and Donald H. Picker, Ph.D., an
individual (the "Executive") with reference to the following facts:

         A. The Company is party to an Agreement and Plan of Merger dated March
10, 2003, as amended April 4, 2003 (the "Merger Agreement") among the Company
(formerly Webtronics, Inc.), Callisto Research Labs, LLC, a Delaware limited
liability company (the successor to Callisto Pharmaceuticals, Inc., a Delaware
corporation) ("Callisto Research"), Synergy Pharmaceuticals, Inc. a Delaware
corporation ("Synergy"), Callisto Acquisition Corp., a Delaware corporation and
Synergy Acquisition Corp., a Delaware corporation.

         B. Pursuant to the Merger Agreement, Callisto Research and Synergy
became subsidiaries of the Company.

         C. Both Callisto Research and Synergy are engaged in the business of
developing and marketing drug products.

         D. Company and Executive desire to enter into an agreement to provide
for Executive's employment by the Company upon the terms and conditions set
forth in this Agreement.

         NOW THEREFORE, in consideration of the foregoing facts and mutual
agreements set forth below, the parties, intending to be legally bound, agree as
follows:

         1. Employment. The Company hereby agrees to employ Executive, and
Executive hereby accepts such employment and agrees to perform Executive's
duties and responsibilities in accordance with the terms and conditions
hereinafter set forth.

               1.1 Duties and Responsibilities. Executive shall serve as Vice
President, Drug Development. During the Employment Term, Executive shall perform
all duties and accept all responsibilities incident to such positions and other
appropriate duties as may be assigned to Executive by the Company's Chief
Scientific Officer, to whom Executive shall report. Executive shall also serve
as an officer of one or more of the Company's subsidiaries without any
additional compensation. The Company shall retain full direction and control of
the manner, means and methods by which Executive performs the services for which
he is employed hereunder and of the place or places at which such services shall
be rendered. Without limiting the forgoing, the Executive acknowledges that
Synergy presently has an office in Somerset, New Jersey and that the Company
will be headquartered in Manhattan, New York and that Executive will be present
in the Company's New York offices not less than normal business hours, unless
Executive is on approved business travel, vacation or it is not a business day.
The Company's normal business hours are 9:00 a.m. to 5:30 p.m. Monday to Friday.

<PAGE>

               1.2 Employment Term. The term of Executive's employment under
this Agreement shall commence on September 23, 2003 (the "Effective Date") and
shall continue for 18 months, unless earlier terminated in accordance with
Section 4 hereof. The term of Executive's employment shall be automatically
renewed for successive one (1) year periods until the Executive or the Company
delivers to the other party a written notice of their intent not to renew the
"Employment Term," such written notice to be delivered at least sixty (60) days
prior to the expiration of the then-effective "Employment Term" as that term is
defined below. The period commencing as of the Effective Date and ending 18
months thereafter or such later date to which the term of Executive's employment
under the Agreement shall have been extended by mutual written Agreement is
referred to herein as the "Employment Term."

               1.3 Extent of Service. During the Employment Term, Executive
agrees to use Executive's best efforts to carry out the duties and
responsibilities under Section 1.1 hereof and to devote substantially all
Executive's business time, attention and energy thereto. Executive further
agrees not to work either on a part-time or independent contracting basis for
any other business or enterprise during the Employment Term without the prior
written consent of the Company's Board of Directors (the "Board"), which consent
shall not be unreasonably withheld.

               1.4 Base Salary. The Company shall pay Executive a base salary
(the "Base Salary") at the annual rate of $175,000 (U.S.), payable at such times
as the Company customarily pays its other senior level executives (but in any
event no less often than monthly). The Base Salary shall be subject to all
state, federal, and local payroll tax withholding and any other withholdings
required by law.

               1.5 Incentive Compensation. Executive shall be eligible to earn a
cash bonus of up to $45,000 for each twelve-month period during the Employment
Term. Executive's bonus, if any, shall be subject to all applicable tax and
payroll withholdings. For the year ending on the first anniversary of the date
of this Agreement, Mr. Picker shall earn:

               (a) $10,000 of his cash bonus upon the closing of the sale of
      Synergy Pharmaceuticals Inc.'s net operating losses which were carried
      over to 2003.

               (b) $10,000 of his cash bonus upon identification of a second
      cancer indication for Atiprimod.

               (c) $10,000 of his cash bonus upon Atiprimod attaining orphan
      drug status from the FDA.

               (d) $15,000 of his cash bonus if Executive arranges a CRADA with
      the FDA to develop Atiprimod analog backup or second generation compound
      or develop in-house capability to develop same.

               1.6 Options. The Board of Directors or if the Board organizes a
compensation committee (the "Committee") having authority over the Company's
1996 Incentive and Non-Qualified Stock Option Plan, in the form that such Plan
is assumed by the Company, under the Merger Agreement (the "Plan"), will make an
initial grant of options to the Executive as follows:

<PAGE>

               (a) a non-qualified performance ten year option to purchase up to
      325,000 Company Common Shares at an exercise price of $1.50 per share,
      which shall vest pursuant to the following schedule: Assuming the
      Executive is employed by the Company on the vesting dates, 83,333 options
      will vest on July 19, 2004, 108,333 options will vest on July 19, 2005 and
      133,334 options will vest on July 19, 2006; and

               (b) the Board or the Committee in exercising its unrestricted
      discretion may grant such additional options to the Executive each year of
      the Employment Term as it deems appropriate.

               1.7 Other Benefits. During the Employment Term, Executive shall
be entitled to participate in all employee benefit plans and programs made
available to the Company's senior level executives as a group or to its
employees generally, as such plans or programs may be in effect from time to
time (the "Benefit Coverages"), including, without limitation, medical, dental,
hospitalization, short-term and long-term disability and life insurance plans,
accidental death and dismemberment protection and travel accident insurance.
Executive shall be provided office space and staff assistance appropriate for
Executive's position and adequate for the performance of his duties.

               1.8 Reimbursement of Expenses; Vacation; Sick Days and Personal
Days. Executive shall be provided with reimbursement of expenses related to
Executive's employment by the Company on a basis no less favorable than that
which may be authorized from time to time by the Board, in its sole discretion,
for senior level executives as a group. Executive shall be entitled to vacation
and holidays in accordance with the Company's normal personnel policies for
senior level executives, but not less than three (3) weeks of vacation per
calendar year, provided Executive shall not utilize more than ten (10)
consecutive business days without the express consent of the Board of Directors.
Unused vacation time will be forfeited as of December 31 of each calendar year
of the Employment Term. Executive shall be entitled to no more than an aggregate
of ten (10 ) sick days and personal days per calendar year.

               1.9 No Other Compensation. Except as expressly provided in
Sections 1.4 through 1.8, Executive shall not be entitled to any other
compensation or benefits.

         2. Confidential Information. Executive recognizes and acknowledges that
by reason of Executive's employment by and service to the Company before, during
and, if applicable, after the Employment Term, Executive will have access to
certain confidential and proprietary information relating to the Company's
business, which may include, but is not limited to, trade secrets, trade
"know-how," product development techniques and plans, formulas, customer lists
and addresses, financing services, funding programs, cost and pricing
information, marketing and sales techniques, strategy and programs, computer
programs and software and financial information (collectively referred to as
"Confidential Information"). Executive acknowledges that such Confidential
Information is a valuable and unique asset of the Company and Executive
covenants that he will not, unless expressly authorized in writing by the
Company, at any time during the course of Executive's employment use any
Confidential Information or divulge or disclose any Confidential Information to
any person, firm or corporation except in connection with the performance of
Executive's duties for the Company and in a manner consistent with the Company's
policies regarding Confidential Information. Executive also covenants that at
any time after the termination of such employment, directly or indirectly, he
will not use any Confidential Information or divulge or disclose any
Confidential Information to any person, firm or corporation, unless such
information is in the public domain through no fault of Executive or except when
required to do so by a court of law, by any governmental agency having
supervisory authority over the business of the Company or by any administrative
or legislative body (including a committee thereof) with apparent jurisdiction
to order Executive to divulge, disclose or make accessible such information. All
written Confidential Information (including, without limitation, in any computer
or other electronic format) which comes into Executive's possession during the
course of Executive's employment shall remain the property of the Company.
Except as required in the performance of Executive's duties for the Company, or
unless expressly authorized in writing by the Company, Executive shall not
remove any written Confidential Information from the Company's premises, except
in connection with the performance of Executive's duties for the Company and in
a manner consistent with the Company's policies regarding Confidential
Information. Upon termination of Executive's employment, the Executive agrees to
return immediately to the Company all written Confidential Information
(including, without limitation, in any computer or other electronic format) in
Executive's possession. As a condition of Executive's continued employment with
the Company and in order to protect the Company's interest in such proprietary
information, the Company shall require Executive's execution of a
Confidentiality Agreement and Inventions Agreement in the form attached hereto
as Exhibit "B", and incorporated herein by this reference.

<PAGE>

         3. Non-Competition; Non-Solicitation.

               3.1 Non-Compete. The Executive hereby covenants and agrees that
during the term of this Agreement and for a period of one year following the end
of the Employment Term, the Executive will not, without the prior written
consent of the Company, directly or indirectly, on his own behalf or in the
service or on behalf of others, whether or not for compensation, engage in any
business activity, or have any interest in any person, firm, corporation or
business, through a subsidiary or parent entity or other entity (whether as a
shareholder, agent, joint venturer, security holder, trustee, partner,
consultant, creditor lending credit or money for the purpose of establishing or
operating any such business, partner or otherwise) with any Competing Business
in the Covered Area. For the purpose of this Section 3.1, (i) "Competing
Business" means any biotechnology or pharmaceutical company, any contract
manufacturer, any research laboratory or other company or entity (whether or not
organized for profit) that has, or is seeking to develop, one or more products
or therapies that is related to azaspiranes and guanylyl cyclase receptor
agonists and (ii) "Covered Area" means all geographical areas of the United
States, Ireland, Germany and other foreign jurisdictions where Company then has
offices and/or sells its products directly or indirectly through distributors
and/or other sales agents. Notwithstanding the foregoing, the Executive may own
shares of companies whose securities are publicly trades, so long as such
securities do not constitute more than one percent (1%) of the outstanding
securities of any such company.

               3.2 Non-Solicitation. The Executive further agrees that as long
as the Agreement remains in effect and for a period of one (1) year from its
termination, the Executive will not divert any business of the Company and/or
its affiliates or any customers or suppliers of the Company and/or the Company's
and/or its affiliates' business to any other person, entity or competitor, or
induce or attempt to induce, directly or indirectly, any person to leave his or
her employment with the Company.

<PAGE>

               3.3 Remedies. The Executive acknowledges and agrees that his
obligations provided herein are necessary and reasonable in order to protect the
Company and its affiliates and their respective business and the Executive
expressly agrees that monetary damages would be inadequate to compensate the
Company and/or its affiliates for any breach by the Executive of his covenants
and agreements set forth herein. Accordingly, the Executive agrees and
acknowledges that any such violation or threatened violation of this Section 3
will cause irreparable injury to the Company and that, in addition to any other
remedies that may be available, in law, in equity or otherwise, the Company and
its affiliates shall be entitled to obtain injunctive relief against he
threatened breach of this Section 3 or the continuation of any such breach by
the Executive without the necessity of proving actual damages.

         4. Termination.

               4.1 By Company. The Company may, in its discretion and at its
option, terminate the Executive's employment with or without Cause, and without
prejudice to any other right or remedy to which the Company or Executive may be
entitled at law or in equity or under this Agreement; provided that the Company
shall only terminate the Executive without Cause with the consent of two of the
three directors appointed by Synergy to the Company's Board pursuant to the
Merger Agreement. In the event the Company desires to terminate the Executive's
employment without Cause, the Company shall give the Executive not less than
ninety (90) days advance written notice. Termination of Executive's employment
hereunder shall be deemed to be "for Cause" in the event that Executive violates
any provisions of this Agreement, is guilty of any criminal act other than minor
traffic violations, is guilty of willful misconduct or gross neglect, or gross
dereliction of his duties hereunder or refuses to perform his duties hereunder
after notice of such refusal to perform such duties or directions was given to
Executive by the Board of Directors.

               4.2 By Executive's Death or Disability. This Agreement shall also
be terminated upon the Executive's death and/or a finding of permanent physical
or mental disability, such disability expected to result in death or to be of a
continuous duration of no less than twelve (12) months, and the Executive is
unable to perform his usual and essential duties for the Company.

               4.3 Compensation on Termination. In the event the Company
terminates Executive's employment, all payments under this Agreement shall
cease, except for Base Salary to the extent already accrued. In the event of
termination by reason of Executive's death and/or permanent disability,
Executive or his executors, legal representatives or administrators, as
applicable, shall be entitled to an amount equal to Executive's Base Salary
accrued through the date of termination, plus a pro rata share of any annual
bonus to which Executive would otherwise be entitled for the year which death or
permanent disability occurs. Upon termination of Executive, if Executive
executes a written release, substantially in the form attached hereto as Exhibit
"C" (the "Release"), of any and all claims against the Company and all related
parties with respect to all matters arising out of Executive's employment by the
Company (other than Executive's entitlement under any employee benefit plan or
program sponsored by the Company in which Executive participated), unless the
Employment Term expires or termination is for Cause, the Executive shall
receive, in full settlement of any claims Executive may have related to his
employment by the Company, Base Salary for 30 calendar days from the date of
termination, provided Executive is in full compliance with the provisions of
Sections 2 and 3 of this Agreement.

<PAGE>

               4.4 Voluntary Termination. Executive may voluntarily terminate
the Employment Term upon sixty (60) days' prior written notice for any reason;
provided, however, that no further payments shall be due under this Agreement in
that event except that Executive shall be entitled to any benefits due under any
compensation or benefit plan provided by the Company for executives or otherwise
outside of this Agreement.

         5. General Provisions.

               5.1 Modification: No Waiver. No modification, amendment or
discharge of this Agreement shall be valid unless the same is in writing and
signed by all parties hereto. Failure of any party at any time to enforce any
provisions of this Agreement or any rights or to exercise any elections hall in
no way be considered to be a waiver of such provisions, rights or elections and
shall in no way affect the validity of this Agreement. The exercise by any party
of any of its rights or any of this elections under this Agreement shall not
preclude or prejudice such party from exercising the same or any other right it
may have under this Agreement irrespective of any previous action taken.

               5.2 Notices. All notices and other communications required or
permitted hereunder or necessary or convenient in connection herewith shall be
in writing and shall be deemed to have been given when hand delivered or mailed
by registered or certified mail as follows (provided that notice of change of
address shall be deemed given only when received):

         If to the Company, to:             Callisto Pharmaceuticals, Inc.
                                            420 Lexington Avenue, Suite 2500
                                            New York, NY 10070

         If to Executive, to:               Donald H. Picker, Ph.D.

Or to such other names or addresses as the Company or Executive, as the case may
be, shall designate by notice to each other person entitled to receive notices
in the manner specified in this Section.

               5.3 Governing Law. This Agreement shall be governed by and
construed in accordance with the laws of the State of Delaware.

<PAGE>

               5.4 Further Assurances. Each party to this Agreement shall
execute all instruments and documents and take all actions as may be reasonably
required to effectuate this Agreement.

               5.5 Severability. Should any one or more of the provisions of
this Agreement or of any agreement entered into pursuant to this Agreement be
determined to be illegal or unenforceable, then such illegal or unenforceable
provision shall be modified by the proper court or arbitrator to the extent
necessary and possible to make such provision enforceable, and such modified
provision and all other provisions of this Agreement and of each other agreement
entered into pursuant to this Agreement shall be given effect separately from
the provisions or portion thereof determined to be illegal or unenforceable and
shall not be affected thereby.

               5.6 Successors and Assigns. Executive may not assign this
Agreement without the prior written consent of the Company. The Company may
assign its rights without the written consent of the executive, so long as the
Company or its assignee complies with the other material terms of this
Agreement. The rights and obligations of the Company under this Agreement shall
inure to the benefit of and be binding upon the successors and permitted assigns
of the Company, and the Executive's rights under this Agreement shall inure to
the benefit of and be binding upon his heirs and executors. The Company's
subsidiaries and controlled affiliates shall be express third party
beneficiaries of this Agreement.

               5.7 Entire Agreement. This Agreement supersedes all prior
agreements and understandings between the parties, oral or written. No
modification, termination or attempted waiver shall be valid unless in writing,
signed by the party against whom such modification, termination or waiver is
sought to be enforced.

               5.8 Counterparts; Facsimile. This Agreement may be executed in
one or more counterparts, each of which shall for all purposes be deemed to be
an original, and all of which taken together shall constitute one and the same
instrument. This Agreement may be executed by facsimile with original signatures
to follow.

         IN WITNESS WHEREOF, the undersigned, intending to be legally bound,
have executed this Agreement as of the date first written above.

                                     CALLISTO PHARMACEUTICALS, INC.

                                     By: /s/ Gary S. Jacob
                                         -----------------

                                     /s/ Donald H. Picker
                                     --------------------
                                     Donald H. Picker, Ph.D.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00058-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00058-of-00352.parquet"}]]